AIM: £4.32 (-0.1) | Nasdaq: $29.80 (-0.65)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Expanded Access
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
Sulanda
®
Launched
Our second novel oncology approved in China
Surufatinib approval In China
and initiation of Chi-Med's first U.S. NDA submission
Watch Interview
Corporate Presentation
Building a global science-focused biopharma from an established base in China
Download Presentation
Surufatinib at ESMO 2020
and SANET-ep & SANET-p results in The Lancet Oncology
Learn More
The Lancet Oncology:
Osimertinib plus Savolitinib in EGFRm+, MET-amplified NSCLC
Read Abstract
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
14 Jan 2021
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Innovation Platform
|
11 Jan 2021
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Innovation Platform
|
30 Dec 2020
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
Innovation Platform
|
29 Dec 2020
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
Group
|
22 Dec 2020
Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference
Current Share Price
London AIM:HCM
£4.32
-0.1 | 25 Feb 2021 | 16:36
Nasdaq AIM:HCM
US$29.80
-0.65 | 25 Feb 2021 | 16:00
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
15 Jan 2021
ASCO-GI 2021: FRESCO-2 global Phase III study of fruquintinib in mCRC
9 Jan 2021
Corporate Presentation
5 Dec 2020
ASH2020: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral PI3Kδ Inhibitor, in Chinese Patients with Relapsed/Refractory Lymphomas
Latest Reports
Interim Report 2020
EN
Annual Report 2019 (with Form 20-F)
EN
Interim Report 2019
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More